How I prevent GVHD in high-risk patients: posttransplant cyclophosphamide and beyond

3.

Bashey

A

,

Zhang

X

,

Jackson

K

, et al.

Comparison of outcomes of hematopoietic cell transplants from T-replete haploidentical donors using post-transplantation cyclophosphamide with 10 of 10 HLA-A, -B, -C, -DRB1, and -DQB1 allele-matched unrelated donors and HLA-identical sibling donors: a multivariable analysis including disease risk index

.

Biol Blood Marrow Transplant

.

2016

. ;

22

(

1

):

125

-

133

.

4.

Bolaños-Meade

J

,

Reshef

R

,

Fraser

R

, et al.

Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203)

.

Lancet Haematol

.

2019

. ;

6

(

3

):

e132

-

e143

.

5.

Rashidi

A

,

Hamadani

M

,

Zhang

MJ

, et al.

Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission

.

Blood Adv

.

2019

. ;

3

(

12

):

1826

-

1836

.

6.

Elmariah

H

,

Kasamon

YL

,

Zahurak

M

, et al.

Haploidentical bone marrow transplantation with post-transplant cyclophosphamide using non-first-degree related donors

.

Biol Blood Marrow Transplant

.

2018

. ;

24

(

5

):

1099

-

1102

.

7.

Shaw

BE

,

Jimenez-Jimenez

AM

,

Burns

LJ

, et al.

National Marrow Donor Program-Sponsored multicenter, phase II trial of HLA-mismatched unrelated donor bone marrow transplantation using post-transplant cyclophosphamide

.

J Clin Oncol

.

2021

. ;

39

(

18

):

1971

-

1982

.

8.

Luznik

L

,

O’Donnell

PV

,

Symons

HJ

, et al.

HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide

.

Biol Blood Marrow Transplant

.

2008

. ;

14

(

6

):

641

-

650

.

9.

Kasamon

YL

,

Ambinder

RF

,

Fuchs

EJ

, et al.

Prospective study of nonmyeloablative, HLA-mismatched unrelated BMT with high-dose posttransplantation cyclophosphamide

.

Blood Adv

.

2017

. ;

1

(

4

):

288

-

292

.

10.

Gragert

L

,

Eapen

M

,

Williams

E

, et al.

HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry

.

N Engl J Med

.

2014

. ;

371

(

4

):

339

-

348

.

11.

Beatty

PG

,

Clift

RA

,

Mickelson

EM

, et al.

Marrow transplantation from related donors other than HLA-identical siblings

.

N Engl J Med

.

1985

. ;

313

(

13

):

765

-

771

.

12.

Anasetti

C

,

Beatty

PG

,

Storb

R

, et al.

Effect of HLA incompatibility on graft-versus-host disease, relapse, and survival after marrow transplantation for patients with leukemia or lymphoma

.

Hum Immunol

.

1990

. ;

29

(

2

):

79

-

91

.

13.

Szydlo

R

,

Goldman

JM

,

Klein

JP

, et al.

Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings

.

J Clin Oncol

.

1997

. ;

15

(

5

):

1767

-

1777

.

14.

Rizzieri

DA

,

Koh

LP

,

Long

GD

, et al.

Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution

.

J Clin Oncol

.

2007

. ;

25

(

6

):

690

-

697

.

15.

Ciceri

F

,

Labopin

M

,

Aversa

F

, et al;

Acute Leukemia Working Party (ALWP) of European Blood and Marrow Transplant (EBMT) Group

.

A survey of fully haploidentical hematopoietic stem cell transplantation in adults with high-risk acute leukemia: a risk factor analysis of outcomes for patients in remission at transplantation

.

Blood

.

2008

. ;

112

(

9

):

3574

-

3581

.

16.

O’Donnell

PV

,

Luznik

L

,

Jones

RJ

, et al.

Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide

.

Biol Blood Marrow Transplant

.

2002

. ;

8

(

7

):

377

-

386

.

17.

McCurdy

SR

,

Kasamon

YL

,

Kanakry

CG

, et al.

Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide

.

Haematologica

.

2017

. ;

102

(

2

):

391

-

400

.

18.

Meybodi

MA

,

Cao

W

,

Luznik

L

, et al.

HLA-haploidentical vs matched-sibling hematopoietic cell transplantation: a systematic review and meta-analysis

.

Blood Adv

.

2019

. ;

3

(

17

):

2581

-

2585

.

19.

Luznik

L

,

Pasquini

MC

,

Logan

B

, et al.

Randomized phase III BMT CTN trial of calcineurin inhibitor-free chronic graft-versus-host disease interventions in myeloablative hematopoietic cell transplantation for hematologic malignancies

.

J Clin Oncol

.

2022

. ;

40

(

4

):

356

-

368

.

20.

McCurdy

SR

,

Radojcic

V

,

Tsai

HL

, et al.

Signatures of GVHD and relapse after post-transplant cyclophosphamide revealed by immune profiling and machine learning

.

Blood

.

2022

. ;

139

(

4

):

608

-

623

.

21.

McCurdy

SR

,

Muth

ST

,

Tsai

HL

, et al.

Early fever after haploidentical bone marrow transplantation correlates with class II HLA-mismatching and myeloablation but not outcomes

.

Biol Blood Marrow Transplant

.

2018

. ;

24

(

10

):

2056

-

2064

.

22.

Imus

PH

,

Blackford

AL

,

Bettinotti

M

, et al.

Severe cytokine release syndrome after haploidentical peripheral blood stem cell transplantation

.

Biol Blood Marrow Transplant

.

2019

. ;

25

(

12

):

2431

-

2437

.

23.

Abboud

R

,

Wan

F

,

Mariotti

J

, et al.

Cytokine release syndrome after haploidentical hematopoietic cell transplantation: an international multicenter analysis

.

Bone Marrow Transplant

.

2021

. ;

56

(

11

):

2763

-

2770

.

24.

Goldsmith

SR

,

Abid

MB

,

Auletta

JJ

, et al.

Posttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysis

.

Blood

.

2021

. ;

137

(

23

):

3291

-

3305

.

25.

Fayard

A

,

Daguenet

E

,

Blaise

D

, et al.

Evaluation of infectious complications after haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide following reduced-intensity and myeloablative conditioning: a study on behalf of the Francophone Society of Stem Cell Transplantation and Cellular Therapy (SFGM-TC)

.

Bone Marrow Transplant

.

2019

. ;

54

(

10

):

1586

-

1594

.

26.

Irene

GC

,

Albert

E

,

Anna

BV

, et al.

Patterns of infection and infectious-related mortality in patients receiving post-transplant high dose cyclophosphamide as graft-versus-host-disease prophylaxis: impact of HLA donor matching

.

Bone Marrow Transplant

.

2021

. ;

56

(

4

):

818

-

827

.

27.

Ruggeri

A

,

Roth-Guepin

G

,

Battipaglia

G

, et al.

Incidence and risk factors for hemorrhagic cystitis in unmanipulated haploidentical transplant recipients

.

Transpl Infect Dis

.

2015

. ;

17

(

6

):

822

-

830

.

28.

Copelan

OR

,

Sanikommu

SR

,

Trivedi

JS

, et al.

Higher incidence of hemorrhagic cystitis following haploidentical related donor transplantation compared with matched related donor transplantation

.

Biol Blood Marrow Transplant

.

2019

. ;

25

(

4

):

785

-

790

.

https://doi.org/10.1016/j.htct.2020.09.149

29.

Gutiérrez-Aguirre

CH

,

Esparza-Sandoval

AC

,

Palomares-Leal

A

,

Jaime-Pérez

JC

,

Gómez-Almaguer

D

,

Cantú-Rodríguez

OG

.

Outpatient haploidentical hematopoietic stem cell transplant using post-transplant cyclophosphamide and incidence of hemorrhagic cystitis

.

Hematol Transfus Cell Ther

.

published online ahead of print 4 December 2020

. .

30.

Arango

M

,

Cardona

D

.

Hemorrhagic cystitis after haploidentical transplantation with post-transplantation cyclophosphamide: protective effect of MESNA continuous infusion

.

Biol Blood Marrow Transplant

.

2020

. ;

26

(

8

):

1492

-

1496

.

31.

Lin

CJ

,

Vader

JM

,

Slade

M

,

DiPersio

JF

,

Westervelt

P

,

Romee

R

.

Cardiomyopathy in patients after posttransplant cyclophosphamide-based hematopoietic cell transplantation

.

Cancer

.

2017

. ;

123

(

10

):

1800

-

1809

.

32.

Yeh

J

,

Whited

L

,

Saliba

RM

, et al.

Cardiac toxicity after matched allogeneic hematopoietic cell transplant in the posttransplant cyclophosphamide era

.

Blood Adv

.

2021

. ;

5

(

24

):

5599

-

5607

.

33.

Duléry

R

,

Mohty

R

,

Labopin

M

, et al.

Early cardiac toxicity associated with post-transplant cyclophosphamide in allogeneic stem cell transplantation

.

JACC CardioOncol

.

2021

. ;

3

(

2

):

250

-

259

.

34.

Imus

PH

,

Tsai

HL

,

DeZern

AE

, et al.

Thrombotic microangiopathy after post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis

.

Biol Blood Marrow Transplant

.

2020

. ;

26

(

12

):

2306

-

2310

.

35.

Epperla

N

,

Li

A

,

Logan

B

, et al.

Incidence, risk factors for and outcomes of transplant-associated thrombotic microangiopathy

.

Br J Haematol

.

2020

. ;

189

(

6

):

1171

-

1181

.

36.

McAdams

MJ

,

Hyder

M

,

Dimitrova

D

, et al.

Phase I/II study of reduced dosing of post-transplantation cyclophosphamide (PTCy) after HLA-haploidentical bone marrow transplantation [abstract]

.

Blood

.

2021

. ;

138

(

suppl 1

). Abstract 101.

37.

Jorge

AS

,

Suárez-Lledó

M

,

Pereira

A

, et al.

Single antigen-mismatched unrelated hematopoietic stem cell transplantation using high-dose post-transplantation cyclophosphamide is a suitable alternative for patients lacking HLA-matched donors

.

Biol Blood Marrow Transplant

.

2018

. ;

24

(

6

):

1196

-

1202

.

38.

Al Malki

MM

,

Tsai

NC

,

Palmer

J

, et al.

Efficacy of post-transplant cyclophosphamide as graft-versus-host disease prophylaxis after peripheral blood stem cell HLA-mismatched unrelated donor hematopoietic cell transplantation; a prospective pilot trial

. [abstract].

Blood

.

2020

. ;

136

(

suppl 1

). Abstract 49-50.

39.

Rappazzo

KC

,

Zahurak

M

,

Bettinotti

M

, et al.

Nonmyeloablative, HLA-mismatched unrelated peripheral blood transplantation with high-dose post-transplantation cyclophosphamide

.

Transplant Cell Ther

.

2021

. ;

27

(

11

):

909.e1

-

909.e6

.

40.

Kasamon

YL

,

Luznik

L

,

Leffell

MS

, et al.

Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome

.

Biol Blood Marrow Transplant

.

2010

. ;

16

(

4

):

482

-

489

.

41.

Raiola

AM

,

Risitano

A

,

Sacchi

N

, et al.

Impact of HLA disparity in haploidentical bone marrow transplantation followed by high-dose cyclophosphamide

.

Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant

.

2018

. ;

24

(

1

):

119

-

126

.

42.

Rashidi

A

,

DiPersio

JF

,

Westervelt

P

, et al.

HLA disparity is not inconsequential in peripheral blood T-replete haploidentical hematopoietic stem cell transplantation

.

Bone Marrow Transplant

.

2016

. ;

51

(

9

):

1275

-

1278

.

43.

Rimando

J

,

Slade

M

,

DiPersio

JF

, et al.

HLA epitope mismatch in haploidentical transplantation is associated with decreased relapse and delayed engraftment

.

Blood Adv

.

2018

. ;

2

(

24

):

3590

-

3601

.

44.

Solomon

SR

,

Aubrey

MA

,

Zhang

X

, et al.

Selecting the best donor for haploidentical transplant: impact of HLA, KIR genotyping, and other clinical variables

.

Biol Blood Marrow Transplant

.

2018

. ;

24

(

4

):

789

-

798

.

45.

Rimando

J

,

Slade

M

,

DiPersio

JF

, et al.

The Predicted Indirectly Recognizable HLA Epitopes (PIRCHE) score for HLA class i graft-versus-host disparity is associated with increased acute graft-versus-host disease in haploidentical transplantation with post-transplantation cyclophosphamide

.

Biol Blood Marrow Transplant

.

2020

. ;

26

(

1

):

123

-

131

.

46.

Fuchs

EJ

,

McCurdy

SR

,

Solomon

SR

, et al.

HLA informs risk predictions after haploidentical stem cell transplantation with post-transplantation cyclophosphamide

.

Blood

.

2022

. ;

139

(

10

):

1452

-

1468

.

47.

Via

CS

,

Rus

V

,

Nguyen

P

,

Linsley

P

,

Gause

WC

.

Differential effect of CTLA4Ig on murine graft-versus-host disease (GVHD) development: CTLA4Ig prevents both acute and chronic GVHD development but reverses only chronic GVHD

.

J Immunol

.

1996

. ;

157

(

9

):

4258

-

4267

.

48.

Watkins

B

,

Qayed

M

,

McCracken

C

, et al.

Phase II trial of costimulation blockade with abatacept for prevention of acute GVHD

.

J Clin Oncol

.

2021

. ;

39

(

17

):

1865

-

1877

.

49.

Kornblit

B

,

Storer

BE

,

Andersen

NS

, et al.

Sirolimus with CSP and MMF as GVHD prophylaxis for allogeneic transplantation with HLA antigen-mismatched donors

.

Blood

.

2020

. ;

136

(

13

):

1499

-

1506

.

50.

Finke

J

,

Bethge

WA

,

Schmoor

C

, et al;

ATG-Fresenius Trial Group

.

Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial

.

Lancet Oncol

.

2009

. ;

10

(

9

):

855

-

864

.

51.

Walker

I

,

Panzarella

T

,

Couban

S

, et al.

Canadian Blood and Marrow Transplant Group. Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial

.

Lancet Oncol

.

2016

. ;

17

(

2

):

164

-

173

.

52.

Battipaglia

G

,

Labopin

M

,

Kröger

N

, et al.

Posttransplant cyclophosphamide vs antithymocyte globulin in HLA-mismatched unrelated donor transplantation

.

Blood

.

2019

. ;

134

(

11

):

892

-

899

.

53.

Nykolyszyn

C

,

Granata

A

,

Pagliardini

T

, et al.

Posttransplantation cyclophosphamide vs. antithymocyte globulin as GVHD prophylaxis for mismatched unrelated hematopoietic stem cell transplantation

.

Bone Marrow Transplant

.

2020

. ;

55

(

2

):

349

-

355

.

54.

Modi

D

,

Kondrat

K

,

Kim

S

, et al.

Post-transplant cyclophosphamide versus thymoglobulin in HLA-mismatched unrelated donor transplant for acute myelogenous leukemia and myelodysplastic syndrome

.

Transplant Cell Ther

.

2021

. ;

27

(

9

):

760

-

767

.

55.

Al-Homsi

ASS

,

Cirrone

F

,

Cole

K

, et al.

Post-Transplant Cyclophosphamide, Abatacept, and Short Course of Tacrolimus Combination (CAST) is safe and seems highly effective in preventing graft-versus-host disease following haploidentical peripheral blood stem cell transplantation

. [abstract].

Blood

.

2021

. ;

138

(

suppl 1

). Abstract 3906.

56.

Abboud

R

,

Gao

F

,

Rettig

MP

, et al.

A single-arm, open-label, pilot study of the JAK1 selective inhibitor itacitinib for the prophylaxis of graft-versus-host disease and cytokine release syndrome in T-cell replete haploidentical peripheral blood hematopoietic cell transplantation

. [abstract].

Blood

.

2021

. ;

138

(

suppl 1

). Abstract 100.

57.

McCurdy

SR

,

Zhang

MJ

,

St Martin

A

, et al.

Effect of donor characteristics on haploidentical transplantation with posttransplantation cyclophosphamide

.

Blood Adv

.

2018

. ;

2

(

3

):

299

-

307

.

58.

Bhatt

VR

,

Wang

T

,

Chen

K

, et al.

Chronic graft-versus-host disease, nonrelapse mortality, and disease relapse in older versus younger adults undergoing matched allogeneic peripheral blood hematopoietic cell transplantation: a Center for International Blood and Marrow Transplant Research Analysis

.

Transplant Cell Ther

.

2022

. ;

28

(

1

):

34

-

42

.

59.

Kasamon

YL

,

Bolaños-Meade

J

,

Prince

GT

, et al.

Outcomes of nonmyeloablative HLA-haploidentical blood or marrow transplantation with high-dose post-transplantation cyclophosphamide in older adults

.

J Clin Oncol

.

2015

. ;

33

(

28

):

3152

-

3161

.

60.

Ciurea

SO

,

Shah

MV

,

Saliba

RM

, et al.

Haploidentical transplantation for older patients with acute myeloid leukemia and myelodysplastic syndrome

.

Biol Blood Marrow Transplant

.

2018

. ;

24

(

6

):

1232

-

1236

.

61.

Imus

PH

,

Tsai

HL

,

Luznik

L

, et al.

Haploidentical transplantation using posttransplant cyclophosphamide as GVHD prophylaxis in patients over age 70

.

Blood Adv

.

2019

. ;

3

(

17

):

2608

-

2616

.

62.

Slade

M

,

DiPersio

JF

,

Westervelt

P

,

Vij

R

,

Schroeder

MA

,

Romee

R

.

Haploidentical hematopoietic cell transplant with post-transplant cyclophosphamide and peripheral blood stem cell grafts in older adults with acute myeloid leukemia or myelodysplastic syndrome

.

Biol Blood Marrow Transplant

.

2017

. ;

23

(

10

):

1736

-

1743

.

63.

Bashey

ZA

,

Zhang

X

,

Brown

S

, et al.

Comparison of outcomes following transplantation with T-replete HLA-haploidentical donors using post-transplant cyclophosphamide to matched related and unrelated donors for patients with AML and MDS aged 60 years or older

.

Bone Marrow Transplant

.

2018

. ;

53

(

6

):

756

-

763

.

64.

Devillier

R

,

Legrand

F

,

Rey

J

, et al.

HLA-matched sibling versus unrelated versus haploidentical related donor allogeneic hematopoietic stem cell transplantation for patients aged over 60 years with acute myeloid leukemia: a single-center donor comparison

.

Biol Blood Marrow Transplant

.

2018

. ;

24

(

7

):

1449

-

1454

.

65.

Perales

MA

,

Tomlinson

B

,

Zhang

MJ

, et al.

Alternative donor transplantation for acute myeloid leukemia in patients aged ≥50 years: young HLA-matched unrelated or haploidentical donor?

.

Haematologica

.

2020

. ;

105

(

2

):

407

-

413

.

66.

Robinson

TM

,

Fuchs

EJ

,

Zhang

MJ

, et al.

Acute Leukemia Working Party of the European Society for Blood and Marrow Transplant and the Center for International Blood and Marrow Transplant Research. Related donor transplants: has posttransplantation cyclophosphamide nullified the detrimental effect of HLA mismatch?

.

Blood Adv

.

2018

. ;

2

(

11

):

1180

-

1186

.

67.

Bashey

A

,

Zhang

MJ

,

McCurdy

SR

, et al.

Mobilized peripheral blood stem cells versus unstimulated bone marrow as a graft source for T-cell-replete haploidentical donor transplantation using post-transplant cyclophosphamide

. [published correction appears in J Clin Oncol. 2019;37(6):528].

J Clin Oncol

.

2017

. ;

35

(

26

):

3002

-

3009

.

68.

Storb

R

,

Leisenring

W

,

Anasetti

C

, et al.

Methotrexate and cyclosporine for graft-vs.-host disease prevention: what length of therapy with cyclosporine?

.

Biol Blood Marrow Transplant

.

1997

. ;

3

(

4

):

194

-

201

.

69.

Kansu

E

,

Gooley

T

,

Flowers

MED

, et al.

Administration of cyclosporine for 24 months compared with 6 months for prevention of chronic graft-versus-host disease: a prospective randomized clinical trial

.

Blood

.

2001

. ;

98

(

13

):

3868

-

3870

.

70.

Bacigalupo

A

,

Maiolino

A

,

Van Lint

MT

, et al.

Cyclosporin A and chronic graft versus host disease

.

Bone Marrow Transplant

.

1990

. ;

6

(

5

):

341

-

344

.

71.

Mengarelli

A

,

Iori

AP

,

Romano

A

, et al.

One-year cyclosporine prophylaxis reduces the risk of developing extensive chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation

.

Haematologica

.

2003

. ;

88

(

3

):

315

-

323

.

72.

Burroughs

L

,

Mielcarek

M

,

Leisenring

W

, et al.

Extending postgrafting cyclosporine decreases the risk of severe graft-versus-host disease after nonmyeloablative hematopoietic cell transplantation

.

Transplantation

.

2006

. ;

81

(

6

):

818

-

825

.

73.

Kasamon

YL

,

Fuchs

EJ

,

Zahurak

M

, et al.

Shortened-duration tacrolimus after nonmyeloablative, HLA-haploidentical bone marrow transplantation

.

Biol Blood Marrow Transplant

.

2018

. ;

24

(

5

):

1022

-

1028

.

74.

DeZern

AE

,

Elmariah

H

,

Zahurak

M

, et al.

Shortened-duration immunosuppressive therapy after nonmyeloablative, related HLA-haploidentical or unrelated peripheral blood grafts and post-transplantation cyclophosphamide

.

Biol Blood Marrow Transplant

.

2020

. ;

26

(

11

):

2075

-

2081

.

75.

Scott

BL

.

Allogeneic stem cell transplantation for high-risk acute leukemia and maintenance therapy: no time to waste

.

Blood Adv

.

2020

. ;

4

(

13

):

3200

-

3204

.

76.

Soiffer

RJ

.

Maintenance therapy for high-risk acute leukemia after allogeneic hematopoietic cell transplantation: wait a minute

.

Blood Adv

.

2020

. ;

4

(

13

):

3205

-

3208

.

77.

Maziarz

RT

,

Levis

M

,

Patnaik

MM

, et al.

Midostaurin after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia

.

Bone Marrow Transplant

.

2021

. ;

56

(

5

):

1180

-

1189

.

78.

Burchert

A

,

Bug

G

,

Fritz

LV

, et al.

Sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with FLT3-internal tandem duplication mutation (SORMAIN)

.

J Clin Oncol

.

2020

. ;

38

(

26

):

2993

-

3002

.

79.

Oran

B

,

de Lima

M

,

Garcia-Manero

G

, et al.

A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients

. [published correction appears in Blood Adv. 2021;5(6):1755-1756].

Blood Adv

.

2020

. ;

4

(

21

):

5580

-

5588

.

80.

Bachanova

V

,

Marks

DI

,

Zhang

MJ

, et al.

Ph+ ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: impact of tyrosine kinase inhibitor and minimal residual disease

.

Leukemia

.

2014

. ;

28

(

3

):

658

-

665

.

81.

Brissot

E

,

Labopin

M

,

Beckers

MM

, et al.

Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia

.

Haematologica

.

2015

. ;

100

(

3

):

392

-

399

.

82.

DeFilipp

Z

,

Ancheta

R

,

Liu

Y

, et al.

Maintenance tyrosine kinase inhibitors following allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia: a Center for International Blood and Marrow Transplant Research Study

.

Biol Blood Marrow Transplant

.

2020

. ;

26

(

3

):

472

-

479

.

83.

Kebriaei

P

,

Banerjee

PP

,

Ganesh

C

, et al.

Blinatumomab is well tolerated maintenance therapy following allogeneic hematopoietic cell transplantation for acute lymphoblastic leukemia

.

Blood

.

2019

. ;

134

(

suppl 1

):

1298

.

84.

Fathi

AT

,

Li

S

,

Soiffer

RJ

, et al.

A phase I study of the IDH2 inhibitor enasidenib as maintenance therapy for IDH2-mutant myeloid neoplasms following hematopoietic cell transplantation [abstract]

.

Blood

.

2020

. ;

136

(

suppl 1

). Abstract 4-5.

85.

Storb

R

,

Deeg

HJ

,

Whitehead

J

, et al.

Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia

.

N Engl J Med

.

1986

. ;

314

(

12

):

729

-

735

.

86.

Ratanatharathorn

V

,

Nash

RA

,

Przepiorka

D

, et al.

Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation

.

Blood

.

1998

. ;

92

(

7

):

2303

-

2314

.

87.

Nash

RA

,

Antin

JH

,

Karanes

C

, et al.

Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors

.

Blood

.

2000

. ;

96

(

6

):

2062

-

2068

.

88.

Sandmaier

BM

,

Kornblit

B

,

Storer

BE

, et al.

Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial

.

Lancet Haematol

.

2019

. ;

6

(

8

):

e409

-

e418

.

89.

Luznik

L

,

Bolaños-Meade

J

,

Zahurak

M

, et al.

High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease

.

Blood

.

2010

. ;

115

(

16

):

3224

-

3230

.

90.

Kanakry

CG

,

Tsai

HL

,

Bolaños-Meade

J

, et al.

Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS

.

Blood

.

2014

. ;

124

(

25

):

3817

-

3827

.

91.

Kanakry

CG

,

O’Donnell

PV

,

Furlong

T

, et al.

Multi-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioning

.

J Clin Oncol

.

2014

. ;

32

(

31

):

3497

-

3505

.

92.

Ruggeri

A

,

Labopin

M

,

Bacigalupo

A

, et al.

Post-transplant cyclophosphamide for graft-versus-host disease prophylaxis in HLA matched sibling or matched unrelated donor transplant for patients with acute leukemia, on behalf of ALWP-EBMT

.

J Hematol Oncol

.

2018

. ;

11

(

1

):

40

.

93.

Mielcarek

M

,

Furlong

T

,

O’Donnell

PV

, et al.

Posttransplantation cyclophosphamide for prevention of graft-versus-host disease after HLA-matched mobilized blood cell transplantation

.

Blood

.

2016

. ;

127

(

11

):

1502

-

1508

.

94.

Bradstock

KF

,

Bilmon

I

,

Kwan

J

, et al.

Single-agent high-dose cyclophosphamide for graft-versus-host disease prophylaxis in human leukocyte antigen-matched reduced-intensity peripheral blood stem cell transplantation results in an unacceptably high rate of severe acute graft- versus-host disease

.

Biol Blood Marrow Transplant

.

2015

. ;

21

(

5

):

941

-

944

.

95.

Holtick

U

,

Chemnitz

JM

,

Shimabukuro-Vornhagen

A

, et al.

OCTET-CY: a phase II study to investigate the efficacy of post-transplant cyclophosphamide as sole graft-versus-host prophylaxis after allogeneic peripheral blood stem cell transplantation

.

Eur J Haematol

.

2016

. ;

96

(

1

):

27

-

35

.

96.

Kanakry

CG

,

Bolaños-Meade

J

,

Kasamon

YL

, et al.

Low immunosuppressive burden after HLA-matched related or unrelated BMT using posttransplantation cyclophosphamide

.

Blood

.

2017

. ;

129

(

10

):

1389

-

1393

.

97.

Kröger

N

,

Shahnaz Syed Abd Kadir

S

,

Zabelina

T

, et al.

Peritransplantation ruxolitinib prevents acute graft-versus-host disease in patients with myelofibrosis undergoing allogenic stem cell transplantation

.

Biol Blood Marrow Transplant

.

2018

. ;

24

(

10

):

2152

-

2156

.

98.

Zhao

Y

,

Shi

J

,

Luo

Y

, et al.

Calcineurin inhibitors replacement by ruxolitinib as graft-versus-host disease prophylaxis for patients after allogeneic stem cell transplantation

.

Biol Blood Marrow Transplant

.

2020

. ;

26

(

5

):

e128

-

e133

.

99.

Zhang

B

,

Chen

L

,

Zhou

J

, et al.

Ruxolitinib early administration reduces acute GVHD after alternative donor hematopoietic stem cell transplantation in acute leukemia

.

Sci Rep

.

2021

. ;

11

(

1

):

8501

.

100.

Morozova

EV

,

Barabanshikova

MV

,

Moiseev

IS

, et al.

A prospective pilot study of graft-versus-host disease prophylaxis with post-transplantation cyclophosphamide and ruxolitinib in patients with myelofibrosis

.

Acta Haematol

.

2021

. ;

144

(

2

):

158

-

165

.

101.

Merryman

RW

,

Kim

HT

,

Zinzani

PL

, et al.

Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma

.

Blood

.

2017

. ;

129

(

10

):

1380

-

1388

.

102.

Ijaz

A

,

Khan

AY

,

Malik

SU

, et al.

Significant risk of graft-versus-host disease with exposure to checkpoint inhibitors before and after allogeneic transplantation

.

Biol Blood Marrow Transplant

.

2019

. ;

25

(

1

):

94

-

99

.

103.

Armand

P

,

Engert

A

,

Younes

A

, et al.

Nivolumab for relapsed/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 Trial

. [published correction appears in J Clin Oncol. 2018;36(26):2748].

J Clin Oncol

.

2018

. ;

36

(

14

):

1428

-

1439

.

104.

Kasamon

YL

,

de Claro

RA

,

Wang

Y

,

Shen

YL

,

Farrell

AT

,

Pazdur

R

.

FDA approval summary: nivolumab for the treatment of relapsed or progressive classical Hodgkin lymphoma

.

Oncologist

.

2017

. ;

22

(

5

):

585

-

591

.

105.

Oran

B

,

Garcia-Manero

G

,

Saliba

RM

, et al.

Posttransplantation cyclophosphamide improves transplantation outcomes in patients with AML/MDS who are treated with checkpoint inhibitors

.

Cancer

.

2020

. ;

126

(

10

):

2193

-

2205

.

106.

De Philippis

C

,

Legrand-Izadifar

F

,

Bramanti

S

, et al.

Checkpoint inhibition before haploidentical transplantation with posttransplant cyclophosphamide in Hodgkin lymphoma

.

Blood Adv

.

2020

. ;

4

(

7

):

1242

-

1249

.

107.

Paul

S

,

Zahurak

M

,

Luznik

L

, et al.

Non-myeloablative allogeneic transplantation with post-transplant cyclophosphamide after immune checkpoint inhibition for classic Hodgkin lymphoma: a retrospective cohort study

.

Biol Blood Marrow Transplant

.

2020

. ;

26

(

9

):

1679

-

1688

.

108.

Merryman

RW

,

Castagna

L

,

Giordano

L

, et al.

Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma

.

Leukemia

.

2021

. ;

35

(

9

):

2672

-

2683

.

109.

Tsai

T

,

Goodman

S

,

Saez

R

, et al.

Allogeneic bone marrow transplantation in patients who relapse after autologous transplantation

.

Bone Marrow Transplant

.

1997

. ;

20

(

10

):

859

-

863

.

110.

Porter

DL

,

Luger

SM

,

Duffy

KM

, et al.

Allogeneic cell therapy for patients who relapse after autologous stem cell transplantation

.

Biol Blood Marrow Transplant

.

2001

. ;

7

(

4

):

230

-

238

.

111.

Branson

K

,

Chopra

R

,

Kottaridis

PD

, et al.

Role of nonmyeloablative allogeneic stem-cell transplantation after failure of autologous transplantation in patients with lymphoproliferative malignancies

.

J Clin Oncol

.

2002

. ;

20

(

19

):

4022

-

4031

.

112.

Sarina

B

,

Castagna

L

,

Farina

L

, et al.

Gruppo Italiano Trapianto di Midollo Osseo. Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availability

.

Blood

.

2010

. ;

115

(

18

):

3671

-

3677

.

113.

Robinson

SP

,

Boumendil

A

,

Finel

H

, et al.

Reduced intensity allogeneic stem cell transplantation for follicular lymphoma relapsing after an autologous transplant achieves durable long-term disease control: an analysis from the Lymphoma Working Party of the EBMT

.

Ann Oncol

.

2016

. ;

27

(

6

):

1088

-

1094

.

114.

Sakurai

M

,

Mori

T

,

Kato

K

, et al;

Adult Lymphoma Working Group of the Japan Society for Hematopoietic Cell Transplantation (JSHCT)

.

Outcome of allogeneic hematopoietic stem cell transplantation for follicular lymphoma relapsing after autologous transplantation: analysis of the Japan Society for Hematopoietic Cell Transplantation

.

Bone Marrow Transplant

.

2021

. ;

56

(

6

):

1462

-

1466

.

115.

Mariotti

J

,

Devillier

R

,

Bramanti

S

, et al.

T cell-replete haploidentical transplantation with post-transplantation cyclophosphamide for Hodgkin lymphoma relapsed after autologous transplantation: reduced incidence of relapse and of chronic graft-versus-host disease compared with HLA-identical related donors

.

Biol Blood Marrow Transplant

.

2018

. ;

24

(

3

):

627

-

632

.

116.

Ruggeri

A

,

Labopin

M

,

Bacigalupo

A

, et al.

Bone marrow versus mobilized peripheral blood stem cells in haploidentical transplants using posttransplantation cyclophosphamide

.

Cancer

.

2018

. ;

124

(

7

):

1428

-

1437

.

117.

Im

A

,

Rashidi

A

,

Wang

T

, et al.

Risk factors for graft-versus-host disease in haploidentical hematopoietic cell transplantation using post-transplant cyclophosphamide

.

Biol Blood Marrow Transplant

.

2020

. ;

26

(

8

):

1459

-

1468

.

118.

Burroughs

LM

,

O’Donnell

PV

,

Sandmaier

BM

, et al.

Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma

.

Biol Blood Marrow Transplant

.

2008

. ;

14

(

11

):

1279

-

1287

.

119.

Castagna

L

,

Busca

A

,

Bramanti

S

, et al.

Haploidentical related donor compared to HLA-identical donor transplantation for chemosensitive Hodgkin lymphoma patients

.

BMC Cancer

.

2020

. ;

20

(

1

):

1140

.

120.

Bolaños-Meade

J

,

Cooke

KR

,

Gamper

CJ

, et al.

Effect of increased dose of total body irradiation on graft failure associated with HLA-haploidentical transplantation in patients with severe haemoglobinopathies: a prospective clinical trial

.

Lancet Haematol

.

2019

. ;

6

(

4

):

e183

-

e193

.

121.

Dew

A

,

Collins

D

,

Artz

A

, et al.

Paucity of HLA-identical unrelated donors for African-Americans with hematologic malignancies: the need for new donor options

.

Biol Blood Marrow Transplant

.

2008

. ;

14

(

8

):

938

-

941

.

122.

Walters

MC

,

Patience

M

,

Leisenring

W

, et al.

Bone marrow transplantation for sickle cell disease

.

N Engl J Med

.

1996

. ;

335

(

6

):

369

-

376

.

123.

Panepinto

JA

,

Walters

MC

,

Carreras

J

, et al;

Non-Malignant Marrow Disorders Working Committee, Center for International Blood and Marrow Transplant Research

.

Matched-related donor transplantation for sickle cell disease: report from the Center for International Blood and Transplant Research

.

Br J Haematol

.

2007

. ;

137

(

5

):

479

-

485

.

124.

Bernaudin

F

,

Socie

G

,

Kuentz

M

, et al;

SFGM-TC

.

Long-term results of related myeloablative stem-cell transplantation to cure sickle cell disease

.

Blood

.

2007

. ;

110

(

7

):

2749

-

2756

.

125.

Locatelli

F

,

Kabbara

N

,

Ruggeri

A

, et al;

Eurocord and European Blood and Marrow Transplantation (EBMT) group

.

Outcome of patients with hemoglobinopathies given either cord blood or bone marrow transplantation from an HLA-identical sibling

.

Blood

.

2013

. ;

122

(

6

):

1072

-

1078

.

126.

Baronciani

D

,

Angelucci

E

,

Potschger

U

, et al.

Hemopoietic stem cell transplantation in thalassemia: a report from the European Society for Blood and Bone Marrow Transplantation Hemoglobinopathy Registry, 2000-2010

.

Bone Marrow Transplant

.

2016

. ;

51

(

4

):

536

-

541

.

127.

Bolaños-Meade

J

,

Fuchs

EJ

,

Luznik

L

, et al.

HLA-haploidentical bone marrow transplantation with posttransplant cyclophosphamide expands the donor pool for patients with sickle cell disease

.

Blood

.

2012

. ;

120

(

22

):

4285

-

4291

.

128.

Fitzhugh

CD

,

Hsieh

MM

,

Taylor

T

, et al.

Cyclophosphamide improves engraftment in patients with SCD and severe organ damage who undergo haploidentical PBSCT

.

Blood Adv

.

2017

. ;

1

(

11

):

652

-

661

.

129.

Saraf

SL

,

Oh

AL

,

Patel

PR

, et al.

Haploidentical peripheral blood stem cell transplantation demonstrates stable engraftment in adults with sickle cell disease

.

Biol Blood Marrow Transplant

.

2018

. ;

24

(

8

):

1759

-

1765

.

130.

de la Fuente

J

,

Dhedin

N

,

Koyama

T

, et al.

Haploidentical bone marrow transplantation with post-transplantation cyclophosphamide plus thiotepa improves donor engraftment in patients with sickle cell anemia: results of an international learning collaborative

.

Biol Blood Marrow Transplant

.

2019

. ;

25

(

6

):

1197

-

1209

.

131.

Pawlowska

AB

,

Cheng

JC

,

Karras

NA

, et al.

HLA haploidentical stem cell transplant with pretransplant immunosuppression for patients with sickle cell disease

.

Biol Blood Marrow Transplant

.

2018

. ;

24

(

1

):

185

-

189

.

132.

DeZern

AE

,

Zahurak

ML

,

Symons

HJ

, et al.

Haploidentical BMT for severe aplastic anemia with intensive GVHD prophylaxis including posttransplant cyclophosphamide

.

Blood Adv

.

2020

. ;

4

(

8

):

1770

-

1779

.

133.

Cao

J

,

Pei

R

,

Zhang

P

, et al.

Successful haploidentical transplantation using plasma exchange and post-transplantation cyclophosphamide for severe aplastic anemia patients with anti-human leukocyte antigen donor-specific antibodies

.

Ann Hematol

.

2021

. ;

100

(

9

):

2381

-

2385

.

134.

Bonfim

C

,

Ribeiro

L

,

Nichele

S

, et al.

Haploidentical bone marrow transplantation with post-transplant cyclophosphamide for children and adolescents with Fanconi anemia

.

Biol Blood Marrow Transplant

.

2017

. ;

23

(

2

):

310

-

317

.

135.

Dimitrova

D

,

Gea-Banacloche

J

,

Steinberg

SM

, et al.

Prospective study of a novel, radiation-free, reduced-intensity bone marrow transplantation platform for primary immunodeficiency diseases

.

Biol Blood Marrow Transplant

.

2020

. ;

26

(

1

):

94

-

106

.

136.

George

B

,

Lionel

S

,

Selvarajan

S

, et al.

An antithymocyte globulin-free conditioning regimen using fludarabine and cyclophosphamide is associated with good outcomes in patients undergoing matched related family donor transplantation for aplastic anemia

.

Transplant Cell Ther

.

2021

. ;

27

(

5

):

409.e1

-

409.e6

.

137.

Li

Y

,

Wang

N

,

Li

L

, et al.

Haploidentical transplantation with modified post-transplantation cyclophosphamide for patients with primary aplastic anemia: a multicenter experience

.

Transplant Cell Ther

.

2021

. ;

27

(

4

):

331.e1

-

331.e7

.

138.

Fernandes

JF

,

Nichele

S

,

Arcuri

LJ

, et al.

Outcomes after haploidentical stem cell transplantation with post-transplantation cyclophosphamide in patients with primary immunodeficiency diseases

.

Biol Blood Marrow Transplant

.

2020

. ;

26

(

10

):

1923

-

1929

.

139.

Arcuri

LJ

,

Nabhan

SK

,

Cunha

R

, et al.

Impact of CD34 cell dose and conditioning regimen on outcomes after haploidentical donor hematopoietic stem cell transplantation with post-transplantation cyclophosphamide for relapsed/refractory severe aplastic anemia

.

Biol Blood Marrow Transplant

.

2020

. ;

26

(

12

):

2311

-

2317

.

140.

Canaani

J

,

Savani

BN

,

Labopin

M

, et al.

Donor age determines outcome in acute leukemia patients over 40 undergoing haploidentical hematopoietic cell transplantation

.

Am J Hematol

.

2018

. ;

93

(

2

):

246

-

253

.

141.

DeZern

AE

,

Franklin

C

,

Tsai

HL

, et al.

Relationship of donor age and relationship to outcomes of haploidentical transplantation with posttransplant cyclophosphamide

.

Blood Adv

.

2021

. ;

5

(

5

):

1360

-

1368

.

142.

Vander Lugt

MT

,

Braun

TM

,

Hanash

S

, et al.

ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death

.

N Engl J Med

.

2013

. ;

369

(

6

):

529

-

539

.

143.

Kanakry

CG

,

Bakoyannis

G

,

Perkins

SM

, et al.

Plasma-derived proteomic biomarkers in human leukocyte antigen-haploidentical or human leukocyte antigen-matched bone marrow transplantation using post-transplantation cyclophosphamide

.

Haematologica

.

2017

. ;

102

(

5

):

932

-

940

.

144.

Papadopoulos

EB

,

Carabasi

MH

,

Castro-Malaspina

H

, et al.

T-cell-depleted allogeneic bone marrow transplantation as postremission therapy for acute myelogenous leukemia: freedom from relapse in the absence of graft-versus-host disease

.

Blood

.

1998

. ;

91

(

3

):

1083

-

1090

.

145.

Solomon

SR

,

Sizemore

CA

,

Sanacore

M

, et al.

Haploidentical transplantation using T cell replete peripheral blood stem cells and myeloablative conditioning in patients with high-risk hematologic malignancies who lack conventional donors is well tolerated and produces excellent relapse-free survival: results of a prospective phase II trial

.

Biol Blood Marrow Transplant

.

2012

. ;

18

(

12

):

1859

-

1866

.

146.

Raj

K

,

Pagliuca

A

,

Bradstock

K

, et al.

Peripheral blood hematopoietic stem cells for transplantation of hematological diseases from related, haploidentical donors after reduced-intensity conditioning

.

Biol Blood Marrow Transplant

.

2014

. ;

20

(

6

):

890

-

895

.

147.

Castagna

L

,

Crocchiolo

R

,

Furst

S

, et al.

Bone marrow compared with peripheral blood stem cells for haploidentical transplantation with a nonmyeloablative conditioning regimen and post-transplantation cyclophosphamide

.

Biol Blood Marrow Transplant

.

2014

. ;

20

(

5

):

724

-

729

.

148.

Cutler

C

,

Logan

B

,

Nakamura

R

, et al.

Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT

.

Blood

.

2014

. ;

124

(

8

):

1372

-

1377

.

149.

Locatelli

F

,

Merli

P

,

Pagliara

D

, et al.

Outcome of children with acute leukemia given HLA-haploidentical HSCT after αβ T-cell and B-cell depletion

.

Blood

.

2017

. ;

130

(

5

):

677

-

685

.